Pharmacyclics (PCYC -0.6%) enrolls a fifth patient in a Phase III trial of its ibrutinib drug...
Pharmacyclics (PCYC -0.6%) enrolls a fifth patient in a Phase III trial of its ibrutinib drug for treating forms of leukemia or lymphoma and triggers a third $50M milestone payment from J&J (JNJ) unit Janssen Biotech. The company may receive up to an extra $675M in milestones, bringing total upfront and milestone payments to $975M. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibodyat Benzinga.com (Fri, 2:31PM)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Thu, 11:07AM)
at Zacks.com (Thu, 9:00AM)
at Benzinga.com (Wed, 5:05PM)
at Benzinga.com (Wed, 2:47PM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs